Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple conversation improve bipolar treatment success?

NCT ID NCT03245593

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether involving bipolar patients in decisions about their long-term medication (shared decision-making) helps them take their medicine as prescribed. Researchers will compare standard care to a shared decision-making plan in 300 adults after a mood episode. The goal is to see if this approach improves adherence, satisfaction, quality of life, and reduces relapses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2018

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient must be available for the 12 months of follow-up * The patient is at least 18 years old * Patients is suffering from bipolar disorder (I or II) according to DSM-5 criteria * Following resolution of a mood episode (manic or depressive according to DSM-5 criteria) according to the criteria of l'International Society for Bipolar Disorder (Recovery, clinical remission of at least 4 weeks) * Followed by at least one of the practitioner belonging to one of the participating centers * Without comprehension problems of fluent French Exclusion Criteria: * The subject is participating in an interventional study, or has participated in another interventional study within the previous 3 months * The subject is in a period of exclusion determined by a previous study * The patient is under safeguard of justice or state guardianship * It is impossible to give the subject informed information, or the subject refuses to sign the consent * The subject has already participated in this study * The patient has troubles linked to the usage of severe intensive substances (such as those defined by the DMS-5) * The patient has a revision of the initial diagnosis of bipolar disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar disorder

Contacts and locations

Locations

  • APHM - Hôpital Sainte-Marguerite

    Marseille, 13274, France

  • APHP - Centre Hospitalier Henri Mondor

    Créteil, 94010, France

  • APHP - Hôpital Saint Louis-Lariboisière-Fernand-Widal

    Paris, 75475, France

  • CH Charles Perrens

    Bordeaux, 33076, France

  • CH Limoges

    Limoges, 87025, France

  • CH Sainte-Marie de Clermont-Ferrand

    Clermont-Ferrand, 63037, France

  • CH le Vinatier

    Bron, 69678, France

  • CHU Nancy

    Nancy, 54000, France

  • CHU Nantes

    Nantes, 44000, France

  • CHU Nimes

    Nîmes, 30029, France

  • CHU de Clermont Ferrand - Hôpital Gabriel-Montpied

    Clermont-Ferrand, 63003, France

  • CHU de Grenoble - Hôpital Albert Michallon

    Grenoble, 38043, France

  • CHU de Montpellier - Hôpital Lapeyronie

    Montpellier, 34295, France

  • Ch Beziers

    Béziers, 34500, France

  • Chu Gabriel Montpied Clermont Ferrand

    Clermont-Ferrand, 63003, France

  • Clinique des troubles thymiques

    Nîmes, 30000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.